Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Precision Medicine and Therapeutic Resistance
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Precision Medicine and Therapeutic Resistance
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

Prognosis-Linked FOXA1 Mutations Alter DNA Binding and Transcription

DOI: 10.1158/2159-8290.CD-RW2020-132 Published November 2020
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major Finding: Mutations linked to estrogen-deprivation response affected FOXA1′s transcription factor activity.

  • Concept: Wing2 mutations increased estrogen response gene expression; SY242CS broadly altered transcription.

  • Impact: This reveals clinically relevant FOXA1 mutations and shows how they alter FOXA1′s function in cells.

FOXA1 is frequently mutated in estrogen receptor–positive (ER+) breast cancer and encodes a pioneer transcription factor that is required for most ER–DNA binding. Arruabarrena-Aristorena and colleagues found that common missense mutations in FOXA1 were correlated with shorter progression-free survival in patients with ER+ breast cancer treated with aromatase inhibitors. Mutations of note affected the DNA-binding C-terminal forkhead domain and included one in β strand 3 (SY242CS) and three in Wing2 (H247Y, S250F, and F266L). In ER+ breast cancer cell lines grown in low-estrogen conditions, Wing2 mutations conferred increased proliferation and anchorage-independent growth capabilities. Additionally, in mice with low (basal-level) estrogen levels, xenografts expressing SY242CS-mutant or F266L-mutant FOXA1 exhibited greater growth than xenografts expressing wild-type FOXA1. In vitro, FOXA1 harboring mutations in the Wing2 subdomain had greater binding to ER loci upon estrogen stimulation, and Wing2 mutations caused increased transcription of estrogen response genes. In contrast, SY242CS-mutant FOXA1 occupied thousands of new binding sites on chromatin whether in the presence or absence of estrogen stimulation, and the SY242CS mutation led to increased expression of different genes than those induced by mutations in the Wing2 region, with particular enrichment of transcription of cholesterol, adipogenesis, and proliferation gene signatures—but not estrogen response gene signatures. Notably, the novel binding sites were characterized by a different motif from that bound by wild-type FOXA1, and almost half of the new FOXA1 binding sites observed with the SY242CS-mutant protein exhibited increased chromatin accessibility, consistent with a mechanism in which SY242CS-mutant FOXA1′s affinity for an alternate motif leads to chromatin opening and subsequent transcription at aberrant sites. In agreement with this notion, the top 50 most upregulated genes in SY242CS-mutant cells had substantial overlap with the atypically accessible chromatin sites and aberrant FOXA1 binding sites caused by the SY242CS mutation. Together, these findings demonstrate the clinical relevance of FOXA1 mutations in ER+ breast cancer and illustrate two mechanisms by which these mutations cause altered FOXA1 activity.

Arruabarrena-Aristorena A, Maag JLV, Kittane S, Cai Y, Karthaus WR, Ladewig E, et al. FOXA1 mutations reveal distinct chromatin profiles and influence therapeutic response in breast cancer. Cancer Cell 2020 Sep 3 [Epub ahead of print].

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2020 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 10 (11)
November 2020
Volume 10, Issue 11
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Prognosis-Linked FOXA1 Mutations Alter DNA Binding and Transcription
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Prognosis-Linked FOXA1 Mutations Alter DNA Binding and Transcription
Cancer Discov November 1 2020 (10) (11) 1622; DOI: 10.1158/2159-8290.CD-RW2020-132

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Prognosis-Linked FOXA1 Mutations Alter DNA Binding and Transcription
Cancer Discov November 1 2020 (10) (11) 1622; DOI: 10.1158/2159-8290.CD-RW2020-132
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Cell-Intrinsic Programs Partition Nutrients in Tumor Microenvironment
  • Extrachromosomal DNA Can Promote Oncogene Transcription in Trans
  • Transient Rest Reverses Exhaustion of Chimeric Antigen Receptor T Cells
Show more Research Watch

Breast Cancer

  • Androgen Receptor Functions as a Tumor Suppressor in ER+ Breast Cancer
  • Immunosuppressive Macrophages Limit PARP Inhibitor Efficacy in TNBC
  • Imaging Can Identify PI3Kα-Inhibitor Susceptibility in Breast Cancer
Show more Breast Cancer
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement